Will these Healthcare Sector Stocks Decline? Merck & Co (MRK), Raptor Pharmaceutical Corp. (RPTP)

0
29

Merck & Co., Inc. (NYSE:MRK)

Stock’s Trading Stats:

Merck & Co., Inc. (NYSE:MRK) surged 1.32% yesterday  and closed at $54.41. The company’s market capitalization is at $153.26Billion with an average trading volume of 9.32 Million. The total number of Outstanding Shares Held by the company are 2.78 Billion.

Recent Press Release:

Merck & Co., Inc. (MRK) known as MSD outside the United States and Canada, declared that it has received an ENERGY STAR 2016 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy administration in both the pharmaceutical and industrial sectors.

Merck has been an ENERGY STAR partner since 1995 and recognized by the EPA for 11 successive years, two times as Partner of the Year and now a ninth time for Sustained Excellence.

The award recognizes one Merck manufacturing site that has achieved ENERGY STAR rankings in the top 25 percent of pharmaceutical plant energy performance nationwide: Las Piedras, Puerto Rico.

Also achieving certification this year were office buildings in Cokesbury and Branchburg, N.J., in addition to an office building in Upper Gwynedd, Pa.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

Stock’s Trading Stats:

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) closed at $4.58 yesterday  by showing a increase of 1.55%. The total number of outstanding shares held by the company are 85.24Million with the total market capitalization of $382.78 Million. The number of shares traded on the last trading session are 1.21 Million.

Recent Press Release:

Raptor Pharmaceutical Corp. (RPTP) on March 21, 2016 declared that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days contrast to a standard 300 days. Raptor estimates, based on information offered by physicians, that there are about 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.